Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02431767 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT02431767 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 94 participants.
The verdict
NCT02431767, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
The study will evaluate the safety and tolerability of the PENNVAX®-GP HIV-1 DNA vaccine and interleukin 12 (IL-12) DNA adjuvant, given by intradermal (ID) or intramuscular (IM) injection with electroporation (EP), in healthy, HIV-uninfected adults.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL PENNVAX®-GP HIV-1 DNA vaccine
- BIOLOGICAL Interleukin-12 (IL-12) DNA adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02431767
The ClinicalTrials.gov registry entry for NCT02431767 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02431767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02431767 about?
NCT02431767 is a clinical study titled "Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults". The study will evaluate the safety and tolerability of the PENNVAX®-GP HIV-1 DNA vaccine and interleukin 12 (IL-12) DNA adjuvant, given by intradermal (ID) or intramuscular (IM) injection with electroporation (EP), in healthy, HIV-uninfected adults.
What is the current status of trial NCT02431767?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2015-08. Estimated completion is 2017-12-20.
What interventions are being tested in trial NCT02431767?
The interventions under investigation include: Placebo (BIOLOGICAL), PENNVAX®-GP HIV-1 DNA vaccine (BIOLOGICAL), Interleukin-12 (IL-12) DNA adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT02431767?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.